Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.

Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T.

Cancer Immunol Immunother. 2011 Jul;60(7):1039-45. doi: 10.1007/s00262-011-1019-1. Epub 2011 Apr 26.

PMID:
21519827
[PubMed - indexed for MEDLINE]
2.

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.

Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ.

J Clin Oncol. 2004 Feb 1;22(3):403-15. Epub 2003 Dec 22.

PMID:
14691123
[PubMed - indexed for MEDLINE]
Free Article
3.

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.

Berd D, Maguire HC Jr, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ.

J Clin Oncol. 1997 Jun;15(6):2359-70.

PMID:
9196151
[PubMed - indexed for MEDLINE]
4.

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.

Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ.

Int J Cancer. 2001 Nov;94(4):531-9.

PMID:
11745440
[PubMed - indexed for MEDLINE]
5.

M-Vax: an autologous, hapten-modified vaccine for human cancer.

Berd D.

Expert Rev Vaccines. 2004 Oct;3(5):521-7. Review.

PMID:
15485331
[PubMed - indexed for MEDLINE]
6.

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.

Berd D, Sato T, Mastrangelo MJ.

Cancer Immunol Immunother. 2002 Aug;51(6):320-6. Epub 2002 Jun 6.

PMID:
12111120
[PubMed - indexed for MEDLINE]
7.

Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine.

Berd D.

Vaccine. 2003 Jan 30;21(7-8):795-7. Review.

PMID:
12531362
[PubMed - indexed for MEDLINE]
8.

Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine.

Sato T.

Cancer Immunol Immunother. 1996 Nov;43(3):174-9.

PMID:
9001571
[PubMed - indexed for MEDLINE]
9.

Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.

Schreiber S, Kämpgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, Lindemann A, Dorffner R, Kittler H, Kasteliz F, Küpcü Z, Sinski A, Zatloukal K, Buschle M, Schmidt W, Birnstiel M, Kempe RE, Voigt T, Weber HA, Pehamberger H, Mertelsmann R, Bröcker EB, Wolff K, Stingl G.

Hum Gene Ther. 1999 Apr 10;10(6):983-93.

PMID:
10223732
[PubMed - indexed for MEDLINE]
10.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
[PubMed - indexed for MEDLINE]
11.

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ.

Cancer Immunol Immunother. 2006 Apr;55(4):451-8. Epub 2005 Jul 21.

PMID:
16034562
[PubMed - indexed for MEDLINE]
12.

Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.

Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM.

Clin Cancer Res. 1998 Mar;4(3):619-27.

PMID:
9533529
[PubMed - indexed for MEDLINE]
Free Article
13.

Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.

Baars A, Claessen AM, van den Eertwegh AJ, Gall HE, Stam AG, Meijer S, Giaccone G, Meijer CJ, Scheper RJ, Wagstaff J, Vermorken JB, Pinedo HM.

Ann Oncol. 2000 Aug;11(8):965-70.

PMID:
11038032
[PubMed - indexed for MEDLINE]
Free Article
14.

Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.

Vilella R, Benítez D, Milà J, Lozano M, Vilana R, Pomes J, Tomas X, Costa J, Vilalta A, Malvehy J, Puig S, Mellado B, Martí R, Castel T.

Cancer Immunol Immunother. 2004 Jul;53(7):651-8. Epub 2004 Mar 16.

PMID:
14999431
[PubMed - indexed for MEDLINE]
15.

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK; Southwest Oncology Group.

J Clin Oncol. 2002 Apr 15;20(8):2067-75.

PMID:
11956267
[PubMed - indexed for MEDLINE]
16.

Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.

Ridolfi L, Ridolfi R, Riccobon A, De Paola F, Petrini M, Stefanelli M, Flamini E, Ravaioli A, Verdecchia GM, Trevisan G, Amadori D.

J Immunother. 2003 Mar-Apr;26(2):156-62.

PMID:
12616107
[PubMed - indexed for MEDLINE]
17.

Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.

Sato T, Bullock TN, Eisenlohr LC, Mastrangelo MJ, Berd D.

Clin Immunol Immunopathol. 1997 Dec;85(3):265-72.

PMID:
9400626
[PubMed - indexed for MEDLINE]
18.

[Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].

Baldueva IA, Novik AV, Moiseenko VM, Nekhaeva TL, Danilova AB, Danilov AO, Protsenko SA, Petrova TIu, Uleĭskaia GI, Shchekina LA, Semenova AI, Mikhaĭlichenko TD, Teletaeva GM, Zhabina AS, Volkov NV, Komarov IuI.

Vopr Onkol. 2012;58(2):212-21. Russian.

PMID:
22774527
[PubMed - indexed for MEDLINE]
19.

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

Lotem M, Peretz T, Drize O, Gimmon Z, Ad El D, Weitzen R, Goldberg H, Ben David I, Prus D, Hamburger T, Shiloni E.

Br J Cancer. 2002 May 20;86(10):1534-9.

PMID:
12085200
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.

Jones RC, Kelley M, Gupta RK, Nizze JA, Yee R, Leopoldo Z, Qi K, Stern S, Morton DL.

Ann Surg Oncol. 1996 Sep;3(5):437-45.

PMID:
8876885
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk